Ridgeline Health
$429/mo
68.2% below Wegovy list price
Compounded semaglutide program with monthly clinician check-ins and dose titration included.
SpendSight commission on referral: $38. Disclosed, never affects scores.
My Watchlist / GLP-1 weight loss drugs / Tue Oct 7
Better, or just advertised more?
You track all 4 drugs in the GLP-1 class. The score is built only from clinical evidence; the ad budget is printed next to it so the two never get confused. Pick a drug to open its Marketing Facts label.
4
Drugs on your watchlist[1]
$699M
Their combined ad spend, Jan to Sep 2025[1]
17 pts
Score gap between the biggest advertiser and the class best[2]
1
Active spend alert on your list (Wegovy, Aug 31)
Tracked drugsScore / 9-mo ads
Sorted by ad spend, heaviest first. Scores never include marketing.
Marketing FactsSS-GLP1-2025-09
Marketing Facts
Wegovy (semaglutide)
Nine months ended Sep 2025 / Novo Nordisk
| Amount per period | Value |
|---|---|
| DTC advertising spend[1] | $316M |
| Quality Score[2] | 72/100 |
| Value Ratio (quality per $M of ads) | 0.23 |
| Avg weight loss in registration trial[3] | 15% |
| U.S. list price per month[4] | $1,349.02 |
Alert SS-0417 / triggered 2025-08-31
August ad spend hit $47.5M, 46.5% above the trailing six-month average. No new clinical evidence was published in the same window.
The heaviest advertiser on your list carries the lowest
Quality Score in the class.
Monthly DTC ad spend, Wegovy, Jan to Sep 2025
[1] MediaRadar DTC ad tracking, Jan to Sep 2025. [2] SpendSight composite of ClinicalTrials.gov efficacy, patient outcomes, FDA OpenFDA status and safety profile. [3] SURMOUNT-1 and STEP-1 results via ClinicalTrials.gov. [4] Manufacturer published list price, 2025. Not medical advice.
Class ledger, ranked by Value Ratio
Value Ratio divides the Quality Score by millions of ad dollars. Higher means the reputation is earned, not bought. Select any row to open its label above.
| Drug | Ad spend | Quality | Value Ratio |
|---|
Spend Alerts / your tracked drugs
When the push starts before the data does
SpendSight watches monthly ad spend for every drug on your list and flags breaks from trend. One alert is waiting for your review.
Alert SS-0417 / Wegovy / triggered 2025-08-31 / unread
August spend hit $47.5M, 46.5% above the trailing six-month average of $32.4M. No new clinical evidence was published in the same window. Expect the ask in exam rooms to rise before the data does. Your appointment is Thursday; the chart below shows the surge month by month.
Notice SS-0392 / Mounjaro / 2025-09-30 / reviewed
September spend of $9.2M sat 2.1% above its trailing average, inside the normal band. No action needed. Mounjaro still holds the class-best Value Ratio at 1.02.
Wegovy monthly DTC spend, Jan to Sep 2025
MediaRadar monthly DTC spend, Wegovy, Jan to Sep 2025. The series sums to the $316M nine-month total. Trailing average computed over Feb to Jul.
Telehealth Pricing / GLP-1 programs
$1,349.02 a month is not the only number
If Thursday's conversation lands on a GLP-1, these are the vetted telehealth programs SpendSight prices against the list. Our commission is printed on every listing and never touches a score.
For reference, Wegovy's U.S. list price is $1,349.02 per month before
insurance. Zepbound lists at $1,086.37.
Aster Telemed
$449/mo
66.7% below Wegovy list price
Brand-name savings program navigator plus insurance prior-authorization support.
SpendSight commission on referral: $41. Disclosed, never affects scores.
Corvia Care
$499/mo
63.0% below Wegovy list price
Tirzepatide program with quarterly lab work bundled into the monthly price.
SpendSight commission on referral: $45. Disclosed, never affects scores.
Read before you compare. Compounded semaglutide is not the FDA-approved brand drug,
and the brand's Quality Score does not transfer to it. Bring the difference up on Thursday before
price decides for you. None of this is medical advice.
Manufacturer published list prices, 2025. Program listings are vetted for state licensure and legitimate prescribing.
Exam Room Card / Thursday's ten minutes
Walk in with the questions, not the commercial
Every question below is built from figures on your watchlist, each with its citation. Check the ones you want on the card. Ten minutes goes fast; three or four is plenty.
Dana's card for Dr. Menon
Thu Oct 9, 2:40 PM / Meridian Family Medicine
3 of 5 questions on your card
Citations print on the back
This console is the pre-launch GLP-1 audit. Create your account and your watchlist, alerts and this card carry over the day SpendSight opens, with 500+ more drugs behind them.
Keep my card at launch